Department of Surgery, Leiden University Medical Center, Leiden, Netherlands.
Department of Internal Medicine division Endocrinology, Leiden University Medical Center, Leiden, Netherlands.
BMC Nephrol. 2021 Apr 23;22(1):150. doi: 10.1186/s12882-021-02361-7.
Renal hyperparathyroidism is a disease entity that is complex and poorly understood. Although there are guidelines regarding how to manage this patient group, evidence is scarce. Therefore, this survey-based study aims to map the physicians' attitude in terms of preference for management of renal hyperparathyroidism and the influence of patient and respondent factors.
A survey was sent to Dutch societies of nephrology, endocrinology, and surgeons with interest in endocrine surgery. The survey consisted of eight case vignettes of renal hyperparathyroidism patients who were on hemodialysis and suitable for kidney transplantation, and varied in one of three patient variables import for decision making: age (40 vs. 65 years), parathyroid hormone (40 vs. 90 pmol/L), and serum calcium level (2.25 vs. 2.8 mmol/L). For each case, respondents could choose between maintaining conservative treatment (active vitamin D metabolites), calcimimetics, or subtotal parathyroidectomy as their treatment of choice. Categorical multilevel logistic models were used to investigate the association of patient and respondent variables with treatment preference. The influence of patient variables was determined independently of each other and by means of logistic regression the probabilities of treatment choice were calculated.
In total, 115 surveys were included in the analysis. In 6 out of 8 cases, less than two-thirds of respondents agreed on the most favoured treatment. Among patient characteristics, the main disincentive for respondents not to choose conservative therapy was an elevated serum calcium level (subtotal parathyroidectomy vs conservative OR 93.1, 95%-CI: 48.39-179.07 and calcimimetics vs conservative OR 31.2 95%-CI: 18.58-52.30). Additionally, the most significant treatment differences were found between medical specialties and the experience of the respondents, expressed as the amount of cases the physician was involved in during the past year.
Elevated serum calcium levels were widely recognized and the prime reason for respondents to abandon conservative treatment. However, considerable disagreement in treatment preferences remained throughout the cases, demonstrating the current literature available being inconclusive in guiding physicians. Therefore, a high-quality trial comparing subtotal parathyroidectomy to medical treatment is needed to determine optimal treatment.
肾性甲状旁腺功能亢进症是一种复杂且尚未被充分认识的疾病实体。尽管有关于如何管理此类患者群体的指南,但相关证据仍然有限。因此,本项基于调查的研究旨在探讨医生在管理肾性甲状旁腺功能亢进症方面的偏好,并分析患者和医生因素的影响。
本研究向对内分泌外科感兴趣的荷兰肾脏病学会、内分泌学会和外科医师学会发送了一份调查。该调查包含 8 个肾性甲状旁腺功能亢进症患者的病例简介,这些患者正在接受血液透析且适合进行肾移植,并且在三个对决策具有重要影响的患者变量中的一个变量上有所不同:年龄(40 岁与 65 岁)、甲状旁腺激素(40 与 90 pmol/L)和血清钙水平(2.25 与 2.8 mmol/L)。对于每个病例,受访者可以选择维持保守治疗(活性维生素 D 代谢物)、钙敏感受体激动剂或甲状旁腺次全切除术作为首选治疗方法。使用分类多水平逻辑模型来探讨患者和医生变量与治疗偏好之间的关联。通过逻辑回归,独立确定患者变量的影响,并计算治疗选择的概率。
共纳入 115 份调查进行分析。在 8 个病例中的 6 个中,不到三分之二的受访者对最受青睐的治疗方法表示一致。在患者特征方面,促使受访者不选择保守治疗的主要原因是血清钙水平升高(甲状旁腺次全切除术与保守治疗相比 OR 93.1,95%CI:48.39-179.07;钙敏感受体激动剂与保守治疗相比 OR 31.2,95%CI:18.58-52.30)。此外,在不同医学专业和受访者经验之间还发现了最显著的治疗差异,具体表现为医生在过去一年中参与的病例数量。
血清钙水平升高得到了广泛认可,也是受访者放弃保守治疗的主要原因。然而,在所有病例中仍然存在相当大的治疗偏好差异,这表明目前的文献并不能为医生提供明确的指导。因此,需要进行一项高质量的比较甲状旁腺次全切除术与药物治疗的随机临床试验,以确定最佳治疗方法。